 <h1>Sulfinpyrazone Side Effects</h1><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li>Reviews</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p><i>Applies to sulfinpyrazone: oral capsule, oral tablet</i></p><h3>Gastrointestinal</h3><p>Gastrointestinal symptoms have been the most frequently reported side effects.  Peptic ulcer disease may be exacerbated or reactivated.<sup>[Ref]</sup></p><h3>Hematologic</h3><p>Hematologic side effects including anemia, leukopenia, agranulocytosis, thrombocytopenia, and aplastic anemia have occurred.  Two cases of leukemia following chronic sulfinpyrazone therapy have been reported.   Concomitant drug therapy was also reported and a causal relationship with sulfinpyrazone has not been established.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Dermatologic side effects have been limited to rash.<sup>[Ref]</sup></p><h3>Renal</h3><p>Renal failure has been reported.  Suggested mechanisms have included hypersensitivity induced interstitial nephritis, tubular-interstitial damage due to precipitation of urinary uric acid crystals, and inhibition of renal prostaglandin synthesis.  Urolithiasis and renal colic may occur following initiation of therapy.  Adequate fluid intake and urinary alkalinization are recommended.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Mobilization of urates during initiation of therapy has resulted in musculoskeletal symptoms of acute gouty arthritis.<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Anturane (sulfinpyrazone)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. Mattingly D, Bradley M, Selley PJ "Hazards of sulphinpyrazone." Br Med J 2 (1978): 1786-7</p><p id="ref_3">3. Braun J "Abnormalities of urinary sediment and renal failure following sulfinpyrazone therapy." Arch Intern Med 136 (1976): 1060-1</p><p id="ref_4">4. Walls M, Goral S, Stone W "Acute renal failure due to sulfinpyrazone." Am J Med Sci 315 (1998): 319-21</p><p id="ref_5">5. Keidar S, Kohan R, Levy J, Grenadier E, Palant A, Ben Ari J "Non oliguric acute renal failure after treatment with sulfinpyrazone." Clin Nephrol 17 (1982): 266-7</p><p id="ref_6">6. Howard T, Hoy RH, Warren S, Georgiev M, Selinger H "Acute renal dysfunction due to sulfinpyrazone therapy in post- myocardial infarction cardiomegaly: reversible hypersensitiv interstitial nephritis." Am Heart J 102 (1981): 294-5</p><p id="ref_7">7. Boelaert J, Lijnen P, Robbens E, Rocher A, Daneels R, Schurgers M, Amery A "Impairment of renal function due to sulphinpyrazone after coronary artery bypass surgery: a prospective double-blind study." J Cardiovasc Pharmacol 8 (1986): 386-91</p><p id="ref_8">8. Keidar S, Kohan R, Levy J, et al "Non oliguric acute renal failure after treatment with sulfinpyrazone." Clin Nephrol 17 (1982): 266-7</p><p id="ref_9">9. Lenfant F, Lahet JJ, Volot F, Schafer I, Freysz M, Rochette L "Effects of bupivacaine on human erythrocytes submitted to stress and evidence for an interaction between bupivacaine and flumazenil." Br J Clin Pharmacol 48 (1999): 826-8</p><p id="ref_10">10. Lijnen P, Boelaert J, van Eeghem P, Daneels R, Schurgers M, de Jaegere P, van der Stichele E, Vincke J, Fagard R, Verschueren LJ, Amery A "Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction." Clin Nephrol 19 (1983): 143-6</p><h2>More about sulfinpyrazone</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: antigout agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Gout</li>
<li>Gouty Arthritis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>